Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

Table 1 Patient characteristics of measurable lesion type in talimogene laherparepvec study

	Any Measurable Lesion	Evaluable^a Lesion	Evaluable for overall lesion- type burden^b
	n (%)	n (%)	n (%)
Any	50 (100)	47 (100)	37 (100)
At least 1 baseline uninjected lesion	48 (96.0)	41 (87.2)	35 (94.6)
Baseline uninjected, non-visceral only	26 (52.0)	23 (48.9)	23 (62.2)
At least 1 visceral lesion at baseline	22 (44.0)	15 (31.9)	12 (32.4)

Denominators are the numbers of patients
^aEvaluable indicates at least 2 assessments with valid measurements per investigator
^bEvaluable indicates at least 2 visits with non-missing overall lesion-type burden for each respective patient subgroup, or overall tumor burden for “Any”
All patients received at least one dose of talimogene laherparepvec